In:
Cardiac Failure Review, Radcliffe Media Media Ltd, Vol. 2, No. 1 ( 2016), p. 40-
Abstract:
Heart failure (HF) represents a growing financial burden on healthcare systems and despite therapeutic advances, mortality remains high. Current treatments focus on blocking neurohormonal pathways, such as the renin-angiotensin aldosterone system (RAAS). Recent research has focused on the natriuretic peptide system, which confers beneficial effects in HF, whereas activation of the RAAS and of the sympathetic nervous system has detrimental effects. LCZ696 (sacubutril/valsartan), a first-in-class angiotensin II AT 1 receptor neprilysin inhibitor, has a unique mode of action that targets both pathways. Clinical studies to date indicate that LCZ696 is effective and safe in mild to moderate arterial hypertension and in HF patients with preserved ejection fraction, and has been shown to be superior to enalapril in patients with moderate to severe HF due to reduced left ventricular ejection fraction.
Type of Medium:
Online Resource
ISSN:
2057-7540
DOI:
10.15420/cfr.2016:1:1
Language:
English
Publisher:
Radcliffe Media Media Ltd
Publication Date:
2016
detail.hit.zdb_id:
2960293-2
Permalink